Sort   by:  
 Page size 
UnknownPooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Not available
S-EPMC5089162 | biostudies-literature
UnknownSurvival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.
Not available
S-EPMC4517051 | biostudies-literature
UnknownSurvival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
Not available
S-EPMC4811023 | biostudies-literature
UnknownEfficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials.
Not available
S-EPMC5791828 | biostudies-literature
UnknownEvaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
Not available
S-EPMC5070547 | biostudies-literature
UnknownImatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
Not available
S-EPMC4878082 | biostudies-literature
UnknownOverall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Not available
S-EPMC4672027 | biostudies-literature
UnknownA phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma.
Not available
S-EPMC10288853 | biostudies-literature
UnknownProgrammed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.
Not available
S-EPMC5562434 | biostudies-literature
UnknownEfficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis.
Not available
S-EPMC5559888 | biostudies-literature
Sort   by:  
 Page size